Skip Navigation


Rheumatology Advance Access originally published online on August 9, 2005
Rheumatology 2005 44(12):1483-1491; doi:10.1093/rheumatology/kei047
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow CME/CE:
Take the course for this article:
 Rheumatology Third Quarter 2005 Quiz
Right arrow All Versions of this Article:
44/12/1483    most recent
kei047v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (15)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Zochling, J.
Right arrow Articles by Braun, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zochling, J.
Right arrow Articles by Braun, J.
Related Collections
Right arrow Spondylarthropathies
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2005. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

REVIEW

The current concept of spondyloarthritis with special emphasis on undifferentiated spondyloarthritis

J. Zochling, J. Brandt and J. Braun

Rheumazentrum-Ruhrgebiet, St Josefs-Krankenhaus, Landgrafenstrasse 15, 44652 Herne, Germany.

Correspondence to: J. Braun. E-mail: J.Braun@rheumazentrum-ruhrgebiet.de

KEY WORDS: Undifferentiated spondyloarthritis, Spondyloarthritis, Management, Anti-TNF therapy

The first 150 words of the full text of this article appear below.


   Introduction
 
In a recent international workshop for ankylosing spondylitis (AS), a consensus was reached that the term ‘spondyloarthritis’ is preferable to ‘spondyloarthropathy’, to emphasize the inflammatory nature of these diseases [1]. The term is often quoted in the plural form, ‘the spondyloarthritides’, accentuating that this is a group of similar diseases with distinct clinical features and a common genetic predisposition, rather than one disease with different clinical presentations. The main association recognized is with HLA B27 but it is clear that there are other genes involved, including the interleukin-1 family gene cluster [2, 3].

Irrespective of the subtype of spondyloarthritis (SpA), the main clinical manifestations of this group are inflammatory back pain (IBP), peripheral arthritis, enthesitis and anterior uveitis, while other organ manifestations are rare. Psoriasis and inflammatory bowel disease (IBD)-associated colitis should be considered as basic subtype-defining entities with their own genetic background, rather than . . . [Full Text of this Article]


   Classification of spondyloarthritis
 

   Clinical manifestations of uSpA
 

   Natural history of uSpA
 

   Treatment of uSpA
 
NSAIDs
Corticosteroids
Sulphasalazine
Methotrexate
Leflunomide
Bisphosphonates
Infliximab
Etanercept
Adalimumab
Anakinra

   Conclusions
 

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Ann Rheum DisHome page
J Braun, J Zochling, X Baraliakos, R Alten, G Burmester, K Grasedyck, J Brandt, H Haibel, M Hammer, A Krause, et al.
Efficacy of sulfasalazine in patients with inflammatory back pain due to undifferentiated spondyloarthritis and early ankylosing spondylitis: a multicentre randomised controlled trial
Ann Rheum Dis, September 1, 2006; 65(9): 1147 - 1153.
[Abstract] [Full Text] [PDF]